Exh. 10.0 - Amended Note Purchase Agreement-Quiros-$1,000,000 loan

                         AMENDED NOTE PURCHASE AGREEMENT

      This AMENDED NOTE PURCHASE AGREEMENT (this "Agreement"),  dated as of July
26, 2006,  hereby amends in its entirety  that certain Note  Purchase  Agreement
dated  November 30, 2005,  entered into by and among Medical  Media  Television,
Inc.,  a Florida  corporation  (the  "Company"),  and  William  H.  Quiros  (the
"Purchaser"), for the issuance and sale to the Purchaser of the Note (as defined
below)  of the  Company,  in the  manner,  and upon the  terms,  provisions  and
conditions set forth in this Agreement.

      WHEREAS,  the  parties  desire  that,  upon the terms and  subject  to the
conditions  contained herein,  the Company shall issue and sell to the Purchaser
and the Purchaser shall purchase the Note;

      WHEREAS,  such  issuance  and  sale  will  be made in  reliance  upon  the
provisions of Section 4(2) and/or Rule 506 of Regulation D  ("Regulation  D") of
the  United  States  Securities  Act  of  1933,  as  amended,   and  regulations
promulgated thereunder (the "Securities Act"), or upon such other exemption from
the  registration  requirements  of the  Securities Act as may be available with
respect to the purchase of the Note to be made hereunder.

      NOW, THEREFORE,  in consideration of the  representations,  warranties and
agreements  contained  herein and other  good and  valuable  consideration,  the
receipt and legal adequacy of which is hereby  acknowledged by the parties,  the
Company and the Purchaser hereby agree as follows:

      1.    Purchase and Sale of Note.

            (a)  Terms of Note:  Upon the  following  terms and  subject  to the
conditions  contained herein, the Company shall issue and sell to the Purchaser,
and the Purchaser shall purchase from the Company, a convertible promissory note
in the aggregate  principal  amount of $1,000,000  (the  "Purchase  Price"),  in
substantially  the form attached  hereto as Exhibit A (the "Note"),  pursuant to
the following loan schedule:

                      November 30, 2005           $175,000
                      December 4, 2005            $250,000
                      December 15, 2005           $250,000
                      January 15, 2006            $325,000

      The outstanding  principal amount of the Note, plus any accrued but unpaid
interest  thereon,  shall be due and  payable in cash on the  Maturity  Date (as
defined in the  Note);  provided,  however,  the  Purchaser  shall have the sole
option to convert on the Maturity Date the outstanding  principal  amount of the
Note plus any accrued but unpaid  interest  into such number of shares of Common
Stock of the  Company,  par value $.0005 per share (the  "Common  Stock"),  at a
Conversion  Price equal to a twenty percent (20%)  discount to the  then-current
market  price  based on the  average  closing  price  for the  twenty  (20) days
immediately preceding the conversion, but in no event shall the Conversion Price
be less than $0.166.  The Note shall not be convertible  until the Maturity Date
and shall not be  convertible  such that the  Investor's  overall  Common  Stock
ownership   position  in  the  Company   exceeds  4.99%  (the   "Ownership   Cap
Restriction"); provided, however, that upon the holder of the Note providing the
Company with  sixty-one  (61) days notice (the "Waiver  Notice") that the holder
would like to waive the  Ownership  Cap  Restriction  with  regard to any or all
shares of Common Stock issuable upon exercise of the  conversion  feature of the
Note, this Ownership Cap  Restriction  will be of no force or effect with regard
to all or a portion of the Note  referenced in the Waiver  Notice,  and provided
further that this  Ownership  Cap  Restriction  shall be of no further  force or
effect during the sixty-one  (61) days  immediately  preceding the expiration of
the term of the Note.
<PAGE>

      The Note shall bear interest at a rate of twenty  percent (20%) per annum.
Until such time as all  installments  representing  an aggregate of $450,000 has
been paid to the Company by William H.  Quiros  under a  Convertible  Promissory
Note issued March 16, 2006 (the "March Quiros Note"),  interest  hereunder shall
be paid on a quarterly  basis with the said  interest  payment(s)  being applied
toward the  balance  remaining  unpaid  under the March  Quiros  Note  ("Applied
Interest"). At such time as the entire $450,000 has been received by the Company
under the March Quiros Note [via cash payments  and/or Applied  Interest],  then
all future interest shall accrue,  but will not become due and payable until the
Maturity Date.

      With the  consent of both the Company  and the  Investor,  the Note may be
extended for an  additional  twelve (12) months,  with the terms of the interest
payments  remaining  the same as above.  The  Company  has the option to pay the
principal amount of this Note plus accrued but unpaid interest in a cash payment
at any time prior to the Maturity Date.

            (b) Issuance of  Warrants:  The  Investor  will be issued  2,500,000
warrants to purchase  Common  Stock of the Company  (the  "Warrants").  Warrants
shall be issued on a pro rata basis per the above loan schedule, as follows:

                  November 30, 2005           437,500 warrants
                  December 4, 2005            625,000 warrants
                  December 15, 2005           625,000 warrants
                  January 15, 2005            812,500 warrants

      The  Warrants  shall  have a term of five  (5)  years  and  shall  have an
exercise  price equal to $0.75 per share (the  "Exercise  Price").  The Warrants
shall not be exercisable such that the Investor's overall Common Stock ownership
position in the Company exceeds 4.99%.

            (c)  In   consideration   of  and  in  express   reliance  upon  the
representations,  warranties, covenants, terms and conditions of this Agreement,
the Company  agrees to issue and sell to the Purchaser and the Purchaser  agrees
to purchase the Note.  The closing under this Agreement  (the  "Closing")  shall
take place at the offices of Medical Media Television, Inc., 8406 Benjamin Road,
Suite C, Tampa,  Florida 33634 upon the  satisfaction  of each of the conditions
set forth in Sections 4 and 5 hereof (the "Closing Date").

            (d) The  Investor  is aware that the  Company  filed a  Registration
Statement  on  Form  SB-2  which  was  approved  by the  Securities  &  Exchange
Commission on March 1, 2006 and that a total of 2,500,000 shares of Common Stock
were reserved and  registered  for the  conversion  of this Note.  Any shares of
Common Stock issued to the Investor  upon the  conversion of this Note in excess
of the 2,500,000  shares  registered  under the  effective  Form SB-2 shall have
standard piggyback registration rights.

      2.  Representations,  Warranties  and  Covenants  of  the  Purchaser.  The
Purchaser  hereby makes the  following  representations  and  warranties  to the
Company, and covenants for the benefit of the Company:

            (a) If the Purchaser is an entity,  the Purchaser is a  corporation,
limited liability company or partnership duly incorporated or organized, validly
existing  and in  good  standing  under  the  laws  of the  jurisdiction  of its
incorporation or organization.


                                     - 2 -
<PAGE>

            (b) This Agreement has been duly  authorized,  validly  executed and
delivered by the Purchaser and is a valid and binding  agreement and  obligation
of the Purchaser enforceable against the Purchaser in accordance with its terms,
subject to limitations  on  enforcement  by general  principles of equity and by
bankruptcy  or  other  laws  affecting  the  enforcement  of  creditors'  rights
generally, and the Purchaser has full power and authority to execute and deliver
this Agreement and the other agreements and documents contemplated hereby and to
perform its obligations hereunder and thereunder.

            (c) The  Purchaser  understands  that no  Federal,  state,  local or
foreign  governmental  body or  regulatory  authority  has made any  finding  or
determination relating to the fairness of an investment in any of the Securities
and that no Federal,  state,  local or foreign  governmental  body or regulatory
authority  has  recommended  or  endorsed,  or will  recommend  or endorse,  any
investment in any of the  Securities.  The Purchaser,  in making the decision to
purchase the Securities,  has relied upon independent  investigation  made by it
and has not relied on any information or representations made by third parties.

            (d) The Purchaser  understands that the Securities are being offered
and  sold  to it in  reliance  on  specific  provisions  of  Federal  and  state
securities  laws and that the Company is relying  upon the truth and accuracy of
the representations,  warranties, agreements, acknowledgments and understandings
of the Purchaser set forth herein for purposes of qualifying for exemptions from
registration under the Securities Act, and applicable state securities laws.

            (e) The Purchaser is an "accredited  investor" as defined under Rule
501 of Regulation D promulgated under the Securities Act.

            (f) The  Purchaser is and will be acquiring the  Securities  for its
own account,  and not with a view to any resale or  distribution  of the Note in
whole  or in  part,  in  violation  of the  Securities  Act  or  any  applicable
securities laws.

            (g) The offer and sale of the  Securities  is  intended to be exempt
from  registration  under the  Securities  Act, by virtue of Section 4(2) and/or
Rule 506 of Regulation D  promulgated  under the  Securities  Act. The Purchaser
understands that the Securities purchased hereunder have not been, and may never
be,  registered  under the Securities Act and that none of the Securities can be
sold or transferred  unless they are first  registered  under the Securities Act
and such state and other  securities laws as may be applicable or in the opinion
of counsel for the Company an exemption from  registration  under the Securities
Act is available (and then the  Securities  may be sold or  transferred  only in
compliance  with such  exemption and all applicable  state and other  securities
laws).

            3.    Representations, Warranties and Covenants of the Company. The
Company represents and warrants to the Purchaser, and covenants for the benefit
of the Purchaser, as follows:

            (a) The Company has been duly  incorporated,  validly exists, and is
in good  standing  under the laws of the State of Florida,  with full  corporate
power and authority to own,  lease and operate its properties and to conduct its
business as currently conducted, and is duly registered and qualified to conduct
its business  and is in good  standing in each  jurisdiction  or place where the
nature  of  its  properties  or  the  conduct  of  its  business  requires  such
registration or  qualification,  except where the failure to register or qualify
would not have a  Material  Adverse  Effect.  For  purposes  of this  Agreement,
"Material  Adverse  Effect"  shall mean any effect on the  business,  results of
operations,  prospects,  assets or  financial  condition  of the Company that is
material and adverse to the Company and its subsidiaries  and affiliates  and/or
any  condition,  circumstance,  or  situation  that would  prohibit or otherwise
materially  interfere  with the ability of the Company  from  entering  into and
performing  any of its  obligations  under  this  Agreement  or the  Note in any
material respect.


                                     - 3 -
<PAGE>

            (b) The Note has been duly  authorized  by all  necessary  corporate
action and,  when paid for or issued in accordance  with the terms  hereof,  the
Note  shall be  validly  issued  and  outstanding,  free and clear of all liens,
encumbrances  and rights of refusal of any kind. When the Conversion  Shares are
issued and paid for in  accordance  with the terms of this  Agreement and as set
forth  in the  Note,  such  shares  will be  duly  authorized  by all  necessary
corporate   action  and  validly   issued  and   outstanding,   fully  paid  and
nonassessable,  free and clear of all liens,  encumbrances and rights of refusal
of any kind and the holders shall be entitled to all rights accorded to a holder
of Common Stock.

            (c) The Note and this Agreement (the  "Transaction  Documents") have
been duly  authorized,  validly  executed and delivered on behalf of the Company
and is a valid and binding  agreement and obligation of the Company  enforceable
against the Company in  accordance  with its terms,  subject to  limitations  on
enforcement  by general  principles  of equity and by  bankruptcy  or other laws
affecting the enforcement of creditors'  rights  generally,  and the Company has
full power and  authority to execute and deliver the  Transaction  Documents and
the other  agreements  and  documents  contemplated  hereby and to  perform  its
obligations hereunder and thereunder.

            (d) The execution and delivery of the Transaction  Documents and the
consummation of the transactions  contemplated by this Agreement by the Company,
will not (i)  conflict  with or result in a breach of or a default  under any of
the terms or provisions of, (A) the Company's  certificate of  incorporation  or
by-laws,  or (B) of any material provision of any indenture,  mortgage,  deed of
trust or other material  agreement or instrument to which the Company is a party
or by which it or any of its material properties or assets is bound, (ii) result
in a violation of any material provision of any law, statute,  rule, regulation,
or any existing  applicable decree,  judgment or order by any court,  Federal or
state regulatory body,  administrative agency, or other governmental body having
jurisdiction  over the Company,  or any of its material  properties or assets or
(iii)  result in the creation or  imposition  of any  material  lien,  charge or
encumbrance  upon any  material  property or assets of the Company or any of its
subsidiaries  pursuant to the terms of any  agreement or instrument to which any
of them is a party or by which any of them may be bound or to which any of their
property or any of them is subject except in the case of clauses (i)(B) or (iii)
for any  such  conflicts,  breaches,  or  defaults  or any  liens,  charges,  or
encumbrances which would not have a Material Adverse Effect.

            (e) The sale and issuance of the  Securities in accordance  with the
terms of and in reliance on the accuracy of the Purchaser's  representations and
warranties  set forth in this  Agreement  will be exempt  from the  registration
requirements of the Securities Act.

            (f)  No  consent,  approval  or  authorization  of  or  designation,
declaration or filing with any governmental authority on the part of the Company
is  required  in  connection  with the  valid  execution  and  delivery  of this
Agreement or the offer,  sale or issuance of the Securities or the  consummation
of any other transaction contemplated by this Agreement.

            (g) There is no action,  suit,  claim,  investigation  or proceeding
pending or, to the  knowledge  of the  Company,  threatened  against the Company
which  questions the validity of the Transaction  Documents or the  transactions
contemplated thereby or any action taken or to be taken pursuant thereto.  There
is no action,  suit,  claim,  investigation  or  proceeding  pending  or, to the
knowledge of the Company,  threatened,  against or involving  the Company or any
subsidiary,  or any of their respective properties or assets which, if adversely
determined, is reasonably likely to result in a Material Adverse Effect.


                                     - 4 -
<PAGE>

            (h) The Company  has  complied  and will comply with all  applicable
federal and state  securities  laws in connection  with the offer,  issuance and
sale of the Note hereunder. Neither the Company nor anyone acting on its behalf,
directly or indirectly, has or will sell, offer to sell or solicit offers to buy
the Note, or similar securities to, or solicit offers with respect thereto from,
or enter into any preliminary  conversations  or negotiations  relating  thereto
with,  any  person,  or has  taken or will  take any  action  so as to bring the
issuance  and  sale  of  the  Note  under  the  registration  provisions  of the
Securities  Act and any other  applicable  federal  and state  securities  laws.
Neither the Company nor any of its  affiliates,  nor any person acting on its or
their  behalf,  has  engaged  in any form of  general  solicitation  or  general
advertising  (within the meaning of  Regulation D under the  Securities  Act) in
connection with the Note.

            (i) To the  Company's  knowledge,  neither this  Agreement,  nor the
Schedules  hereto  contain any untrue  statement  of a material  fact or omit to
state a material fact necessary in order to make the  statements  made herein or
therein,  in the light of the circumstances under which they were made herein or
therein, not misleading.

            (j) The  authorized  capital  stock of the  Company  and the  shares
thereof issued and outstanding as of November 15, 2005 are set forth on Schedule
3(j) attached  hereto.  All of the  outstanding  shares of the Common Stock have
been duly and validly authorized, and are fully paid and non-assessable.  Except
as set forth in this  Agreement or on Schedule 3(j) attached  hereto,  as of the
date hereof, no shares of the Common Stock are entitled to preemptive rights and
there are no registration rights or outstanding options, warrants, scrip, rights
to subscribe to, call or commitments of any character whatsoever relating to, or
securities  or rights  convertible  into,  any  shares of  capital  stock of the
Company.  As of the date hereof,  except for as set forth on Schedule  3(j), the
Company  is not a party to any  agreement  granting  registration  rights to any
person with respect to any of its equity or debt securities.  The Company is not
a party to, and its  executive  officers  have no  knowledge  of, any  agreement
restricting  the voting or transfer  of any shares of the  capital  stock of the
Company.  The  offer  and sale of all  capital  stock,  convertible  securities,
rights, warrants, or options of the Company issued prior to the Closing complied
with all applicable  federal and state  securities laws, or no stockholder has a
right of rescission or damages with respect  thereto which is reasonably  likely
to have a Material  Adverse Effect.  The Company has furnished or made available
to the  Purchaser  true and  correct  copies  of the  Company's  Certificate  of
Incorporation  as in  effect on the date  hereof  (the  "Certificate"),  and the
Company's Bylaws as in effect on the date hereof (the "Bylaws").

            (k) So long as the Note remains outstanding,  the Company shall take
all action  necessary  to at all times have  authorized,  and  reserved  for the
purpose of issuance, a sufficient number of shares of Common Stock to effect the
conversion of the Note.

            (l) The Company  has  complied  and will comply with all  applicable
federal and state  securities  laws in connection  with the offer,  issuance and
sale of the Note and the Conversion  Shares  hereunder.  Neither the Company nor
anyone acting on its behalf, directly or indirectly,  has or will sell, offer to
sell or solicit offers to buy any of the Securities,  or similar  securities to,
or solicit  offers with  respect  thereto  from,  or enter into any  preliminary
conversations or negotiations relating thereto with, any person, or has taken or
will  take  any  action  so as to  bring  the  issuance  and  sale of any of the
Securities  under  the  registration   provisions  of  the  Securities  Act  and
applicable state securities laws. Neither the Company nor any of its affiliates,
nor any person acting on its or their behalf, has engaged in any form of general
solicitation  or general  advertising  (within the meaning of Regulation D under
the  Securities  Act)  in  connection  with  the  offer  or  sale  of any of the
Securities.

            (m) The Company  agrees that so long as the Note is  outstanding  or
the Purchaser owns at least 2,000,000  shares of Common Stock on a fully diluted
basis,  the Purchaser  shall have the right to nominate or appoint an individual
to serve as an observer of the Company's board of directors.


                                     - 5 -
<PAGE>

      4. Conditions Precedent to the Obligation of the Company to Sell the Note.
The  obligation  hereunder  of the  Company  to  issue  and sell the Note to the
Purchaser  is subject to the  satisfaction  or waiver,  at or before the Closing
Date, of each of the  conditions set forth below.  These  conditions are for the
Company's  sole benefit and may be waived by the Company at any time in its sole
discretion.

            (a) The Purchaser shall have executed and delivered this Agreement.

            (b) The Purchaser  shall have  performed,  satisfied and complied in
all material respects with all covenants,  agreements and conditions required to
be  performed,  satisfied or complied  with by the  Purchaser at or prior to the
Closing Date.

            (c) The  representations  and  warranties of the Purchaser  shall be
true and correct in all material respects as of the date when made and as of the
Closing  Date as  though  made at that  time,  except  for  representations  and
warranties that are expressly made as of a particular  date, which shall be true
and correct in all material respects as of such date.

            (d) At the Closing Date,  the Purchaser  shall have delivered to the
Company immediately available funds as payment in full of the Purchase Price for
the Note.

      5. Conditions Precedent to the Obligation of the Purchaser to Purchase the
Note. The obligation  hereunder of the Purchaser to acquire and pay for the Note
is subject to the satisfaction or waiver, at or before the Closing Date, of each
of the conditions set forth below. These conditions are for the Purchaser's sole
benefit and may be waived by the Purchaser at any time in its sole discretion.

            (a) The Company shall have  executed and  delivered  the Note,  this
Agreement and any other Transaction Document.

            (b) The Company shall have performed,  satisfied and complied in all
material respects with all covenants,  agreements and conditions required by the
Transaction Documents to be performed, satisfied or complied with by the Company
at or prior to the Closing Date.

            (c) Each of the  representations and warranties of the Company shall
be true and correct in all material  respects as of the date when made and as of
the Closing  Date as though made at that time  (except for  representations  and
warranties that speak as of a particular date),  which shall be true and correct
in all material respects as of such date.

            (d) No  statute,  regulation,  executive  order,  decree,  ruling or
injunction  shall have been  enacted,  entered,  promulgated  or endorsed by any
court or governmental  authority of competent  jurisdiction  which prohibits the
consummation  of any of the  transactions  contemplated  by this Agreement at or
prior to the Closing Date.

            (e) As of the Closing Date, no action,  suit or proceeding before or
by any court or  governmental  agency or body,  domestic  or  foreign,  shall be
pending  against or  affecting  the  Company,  or any of its  properties,  which
questions  the  validity  of  the  Agreement,  the  Note,  or  the  transactions
contemplated  thereby or any action taken or to be take pursuant thereto.  As of
the Closing Date, no action, suit, claim or proceeding before or by any court or
governmental  agency or body,  domestic or foreign,  shall be pending against or
affecting the Company, or any of its properties, which, if adversely determined,
is reasonably likely to result in a Material Adverse Effect.

            (f) No Material  Adverse Effect shall have occurred at or before the
Closing Date.


                                     - 6 -
<PAGE>

            (g) The Company  shall have  delivered  on the  Closing  Date to the
Purchaser a secretary's certificate, dated as of the Closing Date, as to (i) the
resolutions  of  the  board  of  directors  of  the  Company   authorizing   the
transactions  contemplated by this Agreement,  (ii) the  Certificate,  (iii) the
Bylaws, each as in effect at the Closing,  and (iv) the authority and incumbency
of the officers of the Company executing this Agreement and the Note.

            (h)  The   Purchaser   shall  have   received  a  legal  opinion  in
substantially the form annexed hereto as Exhibit B as of the Closing Date.

      6. Legend.  Each Note and certificate  representing the Conversion  Shares
shall be stamped  or  otherwise  imprinted  with a legend  substantially  in the
following  form  (in  addition  to  any  legend  required  by  applicable  state
securities or "blue sky" laws):

            "THE SECURITIES  REPRESENTED BY THIS CERTIFICATE (THE  "SECURITIES")
            HAVE  NOT BEEN  REGISTERED  UNDER  THE  SECURITIES  ACT OF 1933,  AS
            AMENDED (THE "SECURITIES  ACT") OR ANY STATE SECURITIES LAWS AND MAY
            NOT BE SOLD,  TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED
            UNDER THE SECURITIES ACT AND UNDER  APPLICABLE STATE SECURITIES LAWS
            OR PETCARE TELEVISION  NETWORK,  INC. SHALL HAVE RECEIVED AN OPINION
            OF COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES
            ACT AND UNDER THE PROVISIONS OF APPLICABLE  STATE SECURITIES LAWS IS
            NOT REQUIRED."

The  Company  agrees  to  reissue  the Note and  certificates  representing  the
Conversion Shares,  without the legend set forth above if at such time, prior to
making any  transfer  of any such  Securities,  such holder  thereof  shall give
written  notice to the Company  describing the manner and terms of such transfer
and removal as the Company may reasonably  request.  Such proposed transfer will
not be effected until:  (a) the Company has notified such holder that either (i)
in the opinion of its counsel, the registration of the Note or Conversion Shares
under the  Securities  Act is not  required  in  connection  with such  proposed
transfer;  or (ii) a  registration  statement  under the Securities Act covering
such proposed  disposition has been filed by the Company with the Securities and
Exchange  Commission and has become  effective under the Securities Act; and (b)
the Company has  notified  such  holder that  either:  (i) in the opinion of its
counsel,  the registration or  qualification  under the securities or "blue sky"
laws of any state is not required in connection with such proposed  disposition,
or (ii) compliance with applicable  state securities or "blue sky" laws has been
effected.  The Company  will use its best  efforts to respond to any such notice
from a holder within five (5) days. In the case of any proposed  transfer  under
this Section 6, the Company will use reasonable  efforts to comply with any such
applicable  state  securities  or  "blue  sky"  laws,  but  shall in no event be
required, in connection therewith,  to qualify to do business in any state where
it is not then  qualified or to take any action that would  subject it to tax or
to the general service of process in any state where it is not then subject. The
restrictions  on transfer  contained  in this Section 6 shall be in addition to,
and not by way of limitation of, any other restrictions on transfer contained in
any other section of this Agreement.

      7. Fees and  Expenses.  Each party shall pay the fees and  expenses of its
advisors,  counsel,  accountants  and  other  experts,  if any,  and  all  other
expenses,  incurred  by such party  incident  to the  negotiation,  preparation,
execution,  delivery and performance of this Agreement,  provided, however, that
the  Company  shall pay (i)  $10,000 of  non-accountable  fees and  expenses  in
connection  with the due  diligence,  preparation,  negotiation,  execution  and
delivery  of  this  Agreement,  the  Note  and  the  transactions   contemplated
thereunder  and (ii) the costs of any  amendments,  modifications  or waivers of
this Agreement, the Note or any other Transaction Document.


                                     - 7 -
<PAGE>

      8. Indemnification.

            (a) The Company  hereby  agrees to indemnify  and hold  harmless the
Purchaser  and its  officers,  directors,  shareholders,  employees,  agents and
attorneys  against  any  and  all  losses,  claims,  damages,   liabilities  and
reasonable  expenses  (collectively  "Claims")  incurred  by each such person in
connection  with  defending or  investigating  any such  Claims,  whether or not
resulting in any liability to such person,  to which any such indemnified  party
may become  subject,  insofar as such Claims  arise out of or are based upon any
breach of any  representation  or warranty or  agreement  made by the Company in
this Agreement.

            (b) The  Purchaser  hereby agrees to indemnify and hold harmless the
Company  and  its  officers,  directors,  shareholders,  employees,  agents  and
attorneys against any and all losses, claims, damages,  liabilities and expenses
incurred by each such person in connection with defending or  investigating  any
such claims or  liabilities,  whether or not  resulting in any liability to such
person,  to which  any such  indemnified  party  may  become  subject  under the
Securities Act, or under any other statute, at common law or otherwise,  insofar
as such  Claims  arise  out of or are based  upon (i) any  untrue  statement  or
alleged  untrue  statement of a material  fact made by the  Purchaser,  (ii) any
omission or alleged omission of a material fact with respect to the Purchaser or
(iii) any  breach  of any  representation,  warranty  or  agreement  made by the
Purchaser in this Agreement.

      9.  Governing  Law;  Consent  to  Jurisdiction.  This  Agreement  shall be
governed by and  interpreted in accordance with the laws of the State of Florida
without giving effect to the rules  governing the conflicts of laws. Each of the
parties  consents to the  exclusive  jurisdiction  of the Federal  courts  whose
districts  encompass any part of the County of Hillsborough  located in the City
of Tampa in connection  with any dispute arising under this Agreement and hereby
waives,  to the maximum extent  permitted by law, any  objection,  including any
objection based on forum non conveniens,  to the bringing of any such proceeding
in such  jurisdictions.  Each party  waives  its right to a trial by jury.  Each
party to this  Agreement  irrevocably  consents to the service of process in any
such  proceeding  by the mailing of copies  thereof by  registered  or certified
mail,  postage prepaid,  to such party at its address set forth herein.  Nothing
herein shall affect the right of any party to serve  process in any other manner
permitted by law.

      10.  Notices.  All  notices  and  other  communications  provided  for  or
permitted hereunder shall be made in writing by hand delivery, express overnight
courier,  registered  first class mail, or telecopier  (provided that any notice
sent by  telecopier  shall be confirmed by other means  pursuant to this Section
10),  initially to the address set forth  below,  and  thereafter  at such other
address,  notice of which is given in  accordance  with the  provisions  of this
Section.

            (a)   if to the Company:

                  Medical Media Television, Inc.
                  8406 Benjamin Road, Suite C
                  Tampa, Florida 33634
                  Attention: Philip M. Cohen, President/Chief Executive Officer
                  Tel. No.: (813) 888-7330
                  Fax No.:  (813) 888-7375


                                     - 8 -
<PAGE>

                  with a copy to:

                  Bush Ross Gardner Warren & Rudy, P.A.
                  220 S. Franklin St.
                  Tampa, FL  33601
                  Attn:  John N. Giordano
                  Tel. No.:  (813) 224-9255
                  Fax No.:  (813) 223-9620

            (b)   if to the Purchaser:

                  William H. Quiros
                  1112 League Line Road
                  Conroe, TX  77303
                  Tel. No.:  (818) 284-0496
                  Fax No.:  (708) 575-7985


All such  notices  and  communications  shall be deemed to have been duly given:
when delivered by hand, if personally  delivered;  when receipt is acknowledged,
if telecopied; or when actually received or refused if sent by other means.

      11. Assignment.  Neither party may assign,  sell, or transfer to any third
person the rights of such party hereunder; provided, however, that Purchaser may
assign  his  rights  hereunder  to an  entity  wholly  owned and  controlled  by
Purchaser.

      12. Entire Agreement.  This Agreement,  the Note and any other Transaction
Document  constitute the entire  understanding and agreement of the parties with
respect  to  the  subject   matter  hereof  and   supersedes  all  prior  and/or
contemporaneous  oral or written proposals or agreements relating thereto all of
which are merged  herein.  This  Agreement  may not be amended or any  provision
hereof waived in whole or in part,  except by a written amendment signed by both
of the parties.

      13.  Counterparts.  This Agreement may be executed by facsimile  signature
and in counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

                                  [end of page]


                                     - 9 -
<PAGE>

      IN  WITNESS  WHEREOF,  and in  accordance  with the  amendment  provisions
contained herein, the Company and Payee have executed and delivered this Amended
Note  Purchase  Agreement as of July 26, 2006 with an  effective  date as of the
date first written above.


                            MEDICAL MEDIA TELEVISION, INC.


                            By: /s/ Philip M. Cohen
                                ------------------------------------------------
                                 Name: Philip M. Cohen
                                 Title:   President and Chief Executive Officer


                            PURCHASER:


                            By: /s/ William H. Quiros
                               -------------------------------------------------
                                 Name:  William H. Quiros


                                     - 10 -
<PAGE>

                                    EXHIBIT A
                                    ---------
                                  FORM OF NOTE



                                     - 11 -
<PAGE>

                                    EXHIBIT B
                                    ---------
                                 FORM OF OPINION

      1. The Company is a corporation duly incorporated, validly existing and in
good  standing  under the laws of the  State of  Florida  and has the  requisite
corporate  power to own,  lease and operate its  properties  and assets,  and to
carry on its business as presently conducted. The Company is duly qualified as a
foreign corporation to do business and is in good standing in every jurisdiction
in which the failure to so qualify would have a Material Adverse Effect.

      2. The Company has the  requisite  corporate  power and authority to enter
into and perform its obligations  under the  Transaction  Documents and to issue
the  Securities.  The execution,  delivery and  performance  of the  Transaction
Documents  by  the  Company  and  the  consummation  by it of  the  transactions
contemplated  thereby  have been duly and validly  authorized  by all  necessary
corporate  action and no further consent or  authorization of the Company or its
Board of  Directors  is  required.  The  Transaction  Documents  have  been duly
executed  and  delivered,  and the Note  has  been  duly  executed,  issued  and
delivered  by the Company and each  Transaction  Document  constitutes  a legal,
valid and binding obligation of the Company  enforceable  against the Company in
accordance with its respective  terms. The Conversion  Shares are not subject to
any preemptive rights under the Certificate of Incorporation or the Bylaws.

      3. The Note has been duly authorized  and, when delivered  against payment
in full as provided  in the  Purchase  Agreement,  will be validly  issued.  The
Conversion  Shares have been duly  authorized  for issuance,  and when delivered
upon  conversion  or against  payment in full as provided  in the Note,  will be
validly issued, fully paid and nonassessable.

      4. The execution,  delivery and  performance  of and  compliance  with the
terms of the Transaction Documents and the issuance of the Securities do not (a)
violate any provision of the Certificate of Incorporation or Bylaws,  (b) to our
knowledge,  after due inquiry,  conflict  with,  or  constitute a default (or an
event which with notice or lapse of time or both would become a default)  under,
or  give to  others  any  rights  of  termination,  amendment,  acceleration  or
cancellation of, any material  agreement,  mortgage,  deed of trust,  indenture,
note,  bond,  license,  lease  agreement,  instrument or obligation to which the
Company  is a party and which is known to us,  (c) to our  knowledge,  after due
inquiry,  create or impose a lien,  charge or encumbrance on any property of the
Company under any agreement or any  commitment  known to us to which the Company
is a party or by which the  Company  is bound or by which any of its  respective
properties  or assets are bound,  or (d) result in a violation  of any  Federal,
state, local or foreign statute, rule, regulation,  order, judgment,  injunction
or  decree  (including  Federal  and  state  securities  laws  and  regulations)
applicable  to the  Company or by which any  property or asset of the Company is
bound or  affected,  except,  in all cases  other than  violations  pursuant  to
clauses  (a)  and  (d)  above,  for  such  conflicts,   default,   terminations,
amendments,   acceleration,   cancellations   and   violations   as  would  not,
individually or in the aggregate, have a Material Adverse Effect.

      5. No consent, approval or authorization of or designation, declaration or
filing with any  governmental  authority  on the part of the Company is required
under  Federal,  state or local law, rule or  regulation in connection  with the
valid execution,  delivery and performance of the Transaction Documents,  or the
offer, sale or issuance of the Note or the Conversion Shares.


                                     - 12 -
<PAGE>

      6. To our knowledge,  there is no action,  suit,  claim,  investigation or
proceeding  pending or  threatened  against  the  Company  which  questions  the
validity of the Purchase Agreement or the transactions  contemplated  thereby or
any action  taken or to be taken  pursuant  thereto.  There is no action,  suit,
claim,  investigation or proceeding  pending,  or to our knowledge,  threatened,
against or involving  the Company or any of its  properties or assets and which,
if adversely  determined,  is reasonably  likely to result in a Material Adverse
Effect.  There are no  outstanding  orders,  judgments,  injunctions,  awards or
decrees of any court,  arbitrator or governmental or regulatory body against the
Company or any officers or directors of the Company in their capacities as such.

      7.  Conditioned  on the accuracy of the  Purchaser's  representations  and
warranties contained in the Purchase Agreement,  the offer, issuance and sale of
the Note and the offer,  issuance and sale of the Conversion  Shares pursuant to
the  Purchase  Agreement  and the  Note,  as  applicable,  are  exempt  from the
registration requirements of the Securities Act of 1933, as amended.


                                     - 13 -
<PAGE>

                                   SCHEDULE 3j


Medical Media Television, Inc. Capital Stock:

Common Stock:              Authorized Shares:                 100,000,000 shares
                           Outstanding Shares:                20,725,104 shares
                           Par Value:                         $.0005


Preferred Stock:           Total Authorized Shares:           25,000,000 shares
                           Total Outstanding Shares:          4,294,373 shares
                           Par Value:                         Zero

Series A Zero Coupon Preferred Stock:      Authorized Shares:   1,682,044 shares
                                           Outstanding Shares:  1,682,044 shares


Series B Zero Coupon Preferred Stock:      Authorized Shares:   2,612,329 shares
                                           Outstanding Shares:  2,612,329 shares


      OUTSTANDING OPTIONS, WARRANTS, AND OTHER RIGHTS TO ACQUIRE SHARES OF
                         MEDICAL MEDIA TELEVISION, INC.

Outstanding stock options to purchase 5,303 shares of common stock of MMTV.

Outstanding warrants to purchase 8,079,235 shares of common stock of MMTV.

Outstanding preferred shares which will convert into 16,093,989 shares of common
stock of MMTV.

Outstanding  convertible  debentures which will convert into 4,287,952 shares of
common stock of MMTV. These convertible  debentures may be repaid in cash at the
option of the Company.


                                     - 14 -